Patents by Inventor Bernd Kuhn

Bernd Kuhn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS
    Publication number: 20240217928
    Abstract: The invention relates to novel compounds having the general formula I wherein R1, R2, R3, R4, R5, R6, R7, W, m and n are as described herein, composition including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 25, 2024
    Publication date: July 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Karlheinz BAUMANN, Fiona GRUENINGER, Remo HOCHSTRASSER, Bernd KUHN, Federica MORANDI, Emmanuel PINARD
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20240199587
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, X, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: October 20, 2023
    Publication date: June 20, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Machoud AMOUSSA, Joerg BENZ, Niels Kevin BRIAN, Kallie FRISTON, Maude GIROUD, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Camiel John LEAKE, Rainer E. MARTIN, David Friedrich Erhard NIPPA, Fionn Susannah O’HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER, Didier ROMBACH, Philipp Claudio SCHMID, Shounan ZHANG
  • Heterocyclic compounds
    Patent number: 11981661
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: May 14, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Uwe Grether, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
    Publication number: 20240150373
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 9, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20230416251
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: January 24, 2023
    Publication date: December 28, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • Heterocyclic compounds
    Patent number: 11814375
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: November 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • Heterocyclic compounds as monoacylglycerol lipase inhibitors
    Patent number: 11802133
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: October 31, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Charles Bell, Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Buelent Kocer, Carsten Kroll, Bernd Kuhn, Marius Daniel Rinaldo Lutz, Fionn O'Hara, Hans Richter, Martin Ritter, Didier Rombach, Martin Kuratli
  • APPLICATOR DEVICE AND APPLICATOR SYSTEM FOR MEDICAMENT CONTAINERS
    Publication number: 20230241638
    Abstract: The present disclosure relates to an applicator device for depositing a lubricant onto an inside surface of a barrel of a medicament container. The applicator device includes a sprayer defining a longitudinal direction and sized for insertion into an interior of the barrel along the longitudinal direction. The sprayer is operable to eject the lubricant. A centering element is connected to the sprayer and operably engageable with the barrel in a predefined position or orientation to align the sprayer relative to the barrel.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Inventor: Bernd Kuhn
  • 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
    Patent number: 11708354
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: July 25, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20230203056
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, Z, A, L, B, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 29, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Philipp SCHMID
  • BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS
    Publication number: 20230183224
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1, R2 and R3 are as described herein, pharmaceutically acceptable salts thereof, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 15, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Buelent KOCER, Bernd KUHN, Hans RICHTER, Satoshi TSUCHIYA
  • BRAF DEGRADERS
    Publication number: 20230145336
    Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: December 19, 2022
    Publication date: May 11, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS
    Publication number: 20230117324
    Abstract: The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: August 9, 2022
    Publication date: April 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dennis Jul HANSEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Satoshi TSUCHIYA, Rui CHEN
  • Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors
    Patent number: 11608347
    Abstract: The invention provides new heterocyclic compounds having the general formula (Ie) wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ann Petersen, Joerg Benz, Uwe Grether, Benoit Hornsperger, Buelent Kocer, Bernd Kuhn, Hans Richter, Satoshi Tsuchiya, Yangcheng Qiu, Rui Chen
  • EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230054473
    Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • EGFR INHIBITORS
    Publication number: 20230057891
    Abstract: The application provides a compound having the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
    Publication number: 20230050901
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: May 20, 2022
    Publication date: February 16, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
  • EGFR INHIBITORS
    Publication number: 20230034696
    Abstract: The application provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, compositions including the compound and methods of using the compound. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20230024096
    Abstract: The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).
    Type: Application
    Filed: October 28, 2020
    Publication date: January 26, 2023
    Inventors: Martin DUPLESSIS, Delphine GAUFRETEAU, Roman HUTTER, Eleonora JOVCHEVA, Bernd KUHN, Kiel LAZARSKI, Yanke LIANG, Thomas LUEBBERS, Laetitia Janine MARTIN, Rainer E. MARTIN, Barbara Johanna MUELLER, Roger NORCROSS, Philipp SCHMID, Jean-Yves WACH